Select a medication above to begin.
R-lipoic acid
alpha-lipoic acid
Entire Monograph
Reported Uses
- NOTE: see Herb & Supplement Effectiveness Rating Definitions table
- age-related cognitive decline [Insufficient Evidence]
- age-related macular degeneration [Insufficient Evidence]
- age-related testosterone deficiency [Insufficient Evidence]
- alcoholic liver dz [Possibly Ineffective]
- altitude sickness [Possibly Ineffective]
- Alzheimer dz [Insufficient Evidence]
- anthracycline-induced cardiotoxicity [Insufficient Evidence]
- arthralgia, aromatase inhibitor-induced [Insufficient Evidence]
- atrial fibrillation [Insufficient Evidence]
- back pain [Insufficient Evidence]
- beta-thalassemia [Insufficient Evidence]
- bipolar disorder [Insufficient Evidence]
- burning mouth syndrome [Insufficient Evidence]
- CABG [Insufficient Evidence]
- cancer [Insufficient Evidence]
- cardiovascular dz [Insufficient Evidence]
- carpal tunnel syndrome [Insufficient Evidence]
- cataracts [Insufficient Evidence]
- cervical dysplasia [Insufficient Evidence]
- chronic fatigue syndrome [Insufficient Evidence]
- CKD [Insufficient Evidence]
- dementia, HIV/AIDS-related [Possibly Ineffective]
- diabetes mellitus [Possibly Ineffective]
- diabetic nephropathy [Insufficient Evidence]
- diabetic neuropathy [Possibly Effective]
- diabetic retinopathy [Possibly Ineffective]
- dry eye dz [Insufficient Evidence]
- dysmenorrhea [Insufficient Evidence]
- erectile dysfxn [Insufficient Evidence]
- female infertility [Insufficient Evidence]
- fibromyalgia [Insufficient Evidence]
- glaucoma [Insufficient Evidence]
- heart failure [Insufficient Evidence]
- hemorrhoids [Insufficient Evidence]
- hepatotoxicity, toxin-induced [Insufficient Evidence]
- herniated disc [Insufficient Evidence]
- HIV/AIDS [Insufficient Evidence]
- HTN [Insufficient Evidence]
- hyperlipidemia [Possibly Effective]
- hyperprolactinemia, antipsychotic-induced [Insufficient Evidence]
- hypertriglyceridemia [Insufficient Evidence]
- hypotension, orthostatic [Insufficient Evidence]
- impaired glucose tolerance [Insufficient Evidence]
- interstitial cystitis [Insufficient Evidence]
- Lyme dz [Insufficient Evidence]
- male infertility [Insufficient Evidence]
- metabolic effects, antipsychotic-induced [Insufficient Evidence]
- metabolic syndrome [Insufficient Evidence]
- migraine prophylaxis [Insufficient Evidence]
- miscarriage prevention [Insufficient Evidence]
- muscle strength [Insufficient Evidence]
- mushroom toxicity (Amanita phalloides) [Insufficient Evidence]
- neck pain [Insufficient Evidence]
- nephropathy prophylaxis, contrast-induced [Possibly Ineffective]
- neuropathic pain [Insufficient Evidence]
- nonalcoholic fatty liver dz [Insufficient Evidence]
- obesity [Possibly Effective]
- pain, chronic [Insufficient Evidence]
- periodontitis [Insufficient Evidence]
- peripheral arterial dz [Insufficient Evidence]
- peripheral neuropathy, chemo-induced [Insufficient Evidence]
- persistent olfactory dysfxn, post-COVID-19 [Insufficient Evidence]
- polycystic ovary syndrome [Insufficient Evidence]
- preterm labor prevention [Insufficient Evidence]
- radiation exposure [Insufficient Evidence]
- schizophrenia [Insufficient Evidence]
- sciatica [Insufficient Evidence]
- skin aging [Insufficient Evidence]
- tinnitus [Insufficient Evidence]
- vertigo [Insufficient Evidence]
- vitiligo [Insufficient Evidence]
- Wilson dz [Insufficient Evidence]
- wound healing [Insufficient Evidence]
- wrinkled skin [Insufficient Evidence]
Reported Doses
Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely
Effectiveness Ratings
- [see Herb & Supplement Effectiveness Rating Definitions table]
age-related testosterone deficiency
- [Insufficient Evidence]
- Dose: 800 mg PO bid
Alzheimer dz
- [Insufficient Evidence]
- Dose: 600 mg PO qd; Info: used w/ standard tx
anthracycline-induced cardiotoxicity
- [Insufficient Evidence]
- Dose: 600 mg PO qd
arthralgia, aromatase inhibitor-induced
- [Insufficient Evidence]
- Dose: 240 mg PO qd
back pain
- [Insufficient Evidence]
- Dose: 800 mg PO qd
beta-thalassemia
- [Insufficient Evidence]
- Dose: 600 mg PO qd; Info: given before meal
burning mouth syndrome
- [Insufficient Evidence]
- Dose: 600 mg PO qd
CABG
- [Insufficient Evidence]
- Dose: 100 mg PO tid; Start: 2mo before surgery, then cont. x1mo after surgery
carpal tunnel syndrome
- [Insufficient Evidence]
- Dose: 600 mg PO qd; Alt: 600 mg IV qd x30 days, then 600 mg PO qd
cervical dysplasia
- [Insufficient Evidence]
- Dose: 600 mg PO qd
CKD
- [Insufficient Evidence]
- Dose: 1.6 g PO qd
diabetic nephropathy
- [Insufficient Evidence]
- Dose: 450-600 mg IV qd x14 days; Alt: 300-600 mg PO qd; Info: used w/ conventional tx
diabetic neuropathy
- [Possibly Effective]
- Dose: 600-1800 mg/day PO divided qd-tid; Alt: 600-1200 mg IV qd
dysmenorrhea
- [Insufficient Evidence]
- Dose: 600 mg PO qd x5 days; Start: before menstruation; Info: used w/ or w/o mefenamic acid
erectile dysfxn
- [Insufficient Evidence]
- Dose: 600 mg IV qd x14 days; Alt: 800 mg PO bid
heart failure
- [Insufficient Evidence]
- Dose: 600 mg/day PO in divided doses
hemorrhoids
- [Insufficient Evidence]
- Dose: 200 mg PO qd
hepatotoxicity, toxin-induced
- [Insufficient Evidence]
- Dose: 250 mg PO bid
herniated disc
- [Insufficient Evidence]
- Dose: 404 mg PO bid; Info: used w/ steroids, opioids prn
HIV/AIDS
- [Insufficient Evidence]
- Dose: 300 mg PO tid
hyperlipidemia
- [Possibly Effective]
- Dose: 100-1200 mg PO qd
hyperprolactinemia, antipsychotic-induced
- [Insufficient Evidence]
- Dose: 600 mg PO qd
hypertriglyceridemia
- [Insufficient Evidence]
- Dose: 100 mg PO qd
hypotension, orthostatic
- [Insufficient Evidence]
- Dose: 430-788 mg PO qd
impaired glucose tolerance
- [Insufficient Evidence]
- Dose: 600 mg IV qd x14 days; Alt: 800-1200 mg PO qd
interstitial cystitis
- [Insufficient Evidence]
- Dose: 600 mg PO qd
male infertility
- [Insufficient Evidence]
- Dose: 600 mg PO qd; Alt: 300 mg PO bid
metabolic effects, antipsychotic-induced
- [Insufficient Evidence]
- Dose: 600 mg PO qd
metabolic syndrome
- [Insufficient Evidence]
- Dose: 600 mg PO qd
migraine prophylaxis, adult pts
- [Insufficient Evidence]
- Dose: 300-400 mg PO bid
migraine prophylaxis, peds pts
- [Insufficient Evidence]
- Dose: 300 mg PO qd; Info: for pts 10-19 yo; used w/ flunarizine
miscarriage prevention
- [Insufficient Evidence]
- Dose: 100 mg PO qd; Info: used w/ vaginal progesterone
muscle strength
- [Insufficient Evidence]
- Dose: 300 mg PO qd; Start: 150 mg PO qd x2 days
neck pain
- [Insufficient Evidence]
- Dose: 600 mg PO qd
neuropathic pain
- [Insufficient Evidence]
- Dose: 600 mg PO qd; Start: 600 mg PO tid x3wk; Info: used w/ pulsed radiofrequency tx
nonalcoholic fatty liver dz
- [Insufficient Evidence]
- Dose: 600 mg PO bid
obesity, adult pts
- [Possibly Effective]
- Dose: 300-1800 mg PO qd
obesity, peds pts
- [Possibly Effective]
- Dose: 300 mg PO bid; Info: for pts 10-17 yo
pain, chronic
- [Insufficient Evidence]
- Dose: 400 mg PO qd-bid; Info: for pts w/ mild to moderate idiopathic pain
peripheral arterial dz
- [Insufficient Evidence]
- Dose: 300 mg PO bid
peripheral neuropathy, chemo-induced
- [Insufficient Evidence]
- Dose: 240 mg PO qd; Alt: 600 mg PO qd
persistent olfactory dysfxn, post-COVID-19
- [Insufficient Evidence]
- Dose: 300 mg PO bid
polycystic ovary syndrome
- [Insufficient Evidence]
- Dose: 400-2000 mg PO qd; Info: used w/ or w/o inositol
preterm labor prevention
- [Insufficient Evidence]
- Dose: 400 mg PV qhs
radiation exposure, peds pts
- [Insufficient Evidence]
- Dose: 400 mg PO qd
schizophrenia
- [Insufficient Evidence]
- Dose: 100-300 mg PO qd; Info: used w/ antipsychotic tx
sciatica
- [Insufficient Evidence]
- Dose: 600-800 mg PO qd
skin aging
- [Insufficient Evidence]
- Dose: apply 5% cream topically to face bid
tinnitus
- [Insufficient Evidence]
- Dose: 600 mg PO qd
vertigo
- [Insufficient Evidence]
- Dose: 600 mg PO qd
vitiligo
- [Insufficient Evidence]
- Dose: 100 mg PO qd; Info: used w/ phototherapy
wound healing
- [Insufficient Evidence]
- Dose: 300 mg PO 1h prior to and 300 mg PO immediately after hyperbaric O2 tx
Copyright © 2024. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.